Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Now, Eli Lilly, the largest pharmaceutical company in the world in terms of market capitalisation, has launched its own ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

The vote clears the way for a proposed multibillion-dollar expansion of the former Nexus Pharmaceuticals facility.

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with we ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...

Mounjaro is a very big opportunity, given that a significant number of people have diabetes in India, says the CEO ...